RX108-A
/ Suzhou NeuPharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 01, 2023
Phase I study to evaluate Safety and Tolerability of RX108-A Tablets in Patients with advanced Cancer
(ANZCTR)
- P1 | N=20 | Recruiting | Sponsor: NeuPharma Pty Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Trial initiation date • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1